Imagine your immune system is like a security team that has mistakenly started attacking your own insulin-producing cells. This project creates 'peacekeeper' cells that are genetically programmed to find and protect those specific cells. By teaching these peacekeepers exactly where to go, they can stop the attack without shutting down your entire immune system.
Type 1 diabetes currently relies on insulin replacement, which only treats symptoms and does not stop the autoimmune destruction of beta cells. Existing cell therapies lack the precision to target the specific cells causing the disease.
A breakthrough analysis pipeline for TCR sequences, a humanized T1D preclinical mouse model, and proinsulin-carrying nanoparticles for islet targeting.
If you are a therapy developer dealing with low efficacy in polyclonal Treg treatments — this project developed a GMP-compatible manufacturing process for TCR-engineered Tregs that targets specific beta-cell antigens. This allows for a more precise and potent autoimmune suppression.
If you are a manufacturer dealing with poor drug localization in the pancreas — this project developed proinsulin-carrying nanoparticles that selectively accumulate in pancreatic islets. This technology attracts T lymphocytes to the site and reduces inflammation.
If you are a CRO dealing with the lack of accurate human-like testing environments for T1D — this project developed a tailored humanized mouse model. This provides a standardized way to test antigen-specific immune therapies before human trials.
Based on available project data, specific cost or pricing information for the therapy is not provided.
Yes, the project involves world-leading biotechs to establish GMP-compatible manufacturing processes for highly purified TCR-engineered Tregs.
The project has established an Innovation Management Board specifically for IP management to handle the results of the research.
The project aims to deliver a production process and regulatory certificates that allow for the launch of a phase 1 clinical trial immediately after the project ends in June 2030.
Unlike insulin replacement which only treats symptoms, this therapy aims to suppress the immune cells driving the disease to protect insulin-producing cells.
The consortium is well-balanced for clinical translation, featuring 12 partners with a strong 33% industry presence (4 companies, including 2 SMEs). The mix of 5 research institutions and 3 universities across 4 countries (DE, FR, PL, US) ensures a pipeline from basic immunological research to GMP-grade manufacturing.
Contact INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) in France
Contact us to explore licensing opportunities for the TCR-engineered Treg manufacturing process.
